Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2012 1
2015 2
2016 2
2017 8
2018 28
2019 56
2020 75
2021 83
2022 85
2023 69
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Results by year

Filters applied: . Clear all
Page 1
Larotrectinib.
[No authors listed] [No authors listed] 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 36780411 Free Books & Documents. Review.
No information is available on the clinical use of larotrectinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during larotrectinib therapy and for 1 week after the last dose....
No information is available on the clinical use of larotrectinib during breastfeeding. The manufacturer recommends that breastfeeding …
Larotrectinib.
[No authors listed] [No authors listed] 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643418 Free Books & Documents. Review.
Larotrectinib is a selective inhibitor of neurotrophin receptor kinase (NTRK) that is used in the therapy of solid tumors harboring NTRK gene fusions. Larotrectinib is associated with a high rate of serum aminotransferase elevations during therapy but has not been l …
Larotrectinib is a selective inhibitor of neurotrophin receptor kinase (NTRK) that is used in the therapy of solid tumors harboring N …
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Drilon A, et al. N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448. N Engl J Med. 2018. PMID: 29466156 Free PMC article. Clinical Trial.
Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse event …
Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to …
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, Doz F, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A. Hong DS, et al. Lancet Oncol. 2020 Apr;21(4):531-540. doi: 10.1016/S1470-2045(19)30856-3. Epub 2020 Feb 24. Lancet Oncol. 2020. PMID: 32105622 Free PMC article. Clinical Trial.
This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patie …
This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally …
Larotrectinib for solid tumours.
[No authors listed] [No authors listed] Aust Prescr. 2022 Jun;45(3):97-98. doi: 10.18773/austprescr.2022.030. Epub 2022 Jun 1. Aust Prescr. 2022. PMID: 35755993 Free PMC article. Review. No abstract available.
Larotrectinib: First Global Approval.
Scott LJ. Scott LJ. Drugs. 2019 Feb;79(2):201-206. doi: 10.1007/s40265-018-1044-x. Drugs. 2019. PMID: 30635837 Review.
A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with NTRK gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrect …
A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tu …
Larotrectinib: A Targeted Therapy for Solid Tumors.
Mota-George G, Schneider SM. Mota-George G, et al. Clin J Oncol Nurs. 2021 Apr 1;25(2):181-187. doi: 10.1188/21.CJON.181-187. Clin J Oncol Nurs. 2021. PMID: 33739345 Review.
With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by cancer type in the future. OBJECTIVES: This article provides an overview of larotrectinib, a targeted therapy. METHODS: This article …
With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by …
Larotrectinib (LOXO-101).
Berger S, Martens UM, Bochum S. Berger S, et al. Recent Results Cancer Res. 2018;211:141-151. doi: 10.1007/978-3-319-91442-8_10. Recent Results Cancer Res. 2018. PMID: 30069765 Review.
Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally available, selective inhibitor of the TRK receptor family that has already shown substantial clinical benefit in both pediatric and adult patients …
Several TRK inhibitors have been developed, and one of them, Larotrectinib (formerly known as LOXO-101), represents an orally availab …
Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW, Hawkins DS. Laetsch TW, et al. Expert Rev Anticancer Ther. 2019 Jan;19(1):1-10. doi: 10.1080/14737140.2019.1538796. Epub 2018 Oct 24. Expert Rev Anticancer Ther. 2019. PMID: 30350734 Review.
Areas covered: This review covers the current preclinical and clinical evidence for TRK inhibitors for TRK fusion cancers, focusing on larotrectinib. Expert commentary: Larotrectinib has demonstrated a remarkable 75% centrally confirmed objective response rate in pa …
Areas covered: This review covers the current preclinical and clinical evidence for TRK inhibitors for TRK fusion cancers, focusing on la …
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A, Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel JD, Rosen L, Solomon B, Norenberg R, Dima L, Brega N, Shen L, Moreno V, Kummar S, Lin JJ. Drilon A, et al. JCO Precis Oncol. 2022 Jan;6:e2100418. doi: 10.1200/PO.21.00418. JCO Precis Oncol. 2022. PMID: 35085007 Free PMC article.
PURPOSE: Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion-positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy and safety of larotr …
PURPOSE: Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficac …
400 results